3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Nasopharyngeal Carcinoma
3
Triple Negative Breast Neoplasms
2
Esophageal Squamous Cell Carcinoma
2
Carcinoma, Hepatocellular
2
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Salivary Gland Neoplasms
1
Rectal Cancer Patients
1
Pancreatic Neoplasms
1
Locally Advanced Rectal Cancer
1
Esophageal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Interventions
pembrolizumab
24
enfortumab vedotin
14
Nivolumab
14
Gemcitabine
11
Magnetic Resonance Spectroscopy
10
Specimen Handling
9
Cisplatin
8
Carboplatin
8
sacituzumab govitecan
6
Docetaxel
6
avelumab
5
atezolizumab
5
Ipilimumab
5
durvalumab
4
Paclitaxel
4
cabozantinib
3
Taxes
3
Mitomycin
3
CTLA-4 Antigen
3
zanidatamab
2
tislelizumab
2
relatlimab
2
erdafitinib
2
disitamab vedotin
2
Radiosurgery
2
Platinum
2
Oxaliplatin
2
Immunoglobulin G
2
Fluorouracil
2
Disulfides
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Carcinoma, Transitional Cell
×
camrelizumab
×
90 days
×
Clear all
No trials found.